Compare Amgen, Inc. (AMGN) vs Global X Autonomous & Electric Vehicles (DRIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Global X Autonomous & Electric Vehicles — how do they compare? Amgen, Inc. trades at $356.4 (market cap $196.12B), while Global X Autonomous & Electric Vehicles trades at $36. The key difference: Amgen, Inc. pays a 2.77% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals.
| AMGN | DRIV | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $42.53 |
52-Week Low | $271.18 | $23.67 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DRIV trades at $36.54, down 0.12% on the day, with technical indicators signaling a bearish trend. The stock faces selling pressure across moving averages and oscillators, with key resistance at $37. Recent news highlights strong global EV sales growth and China's expanding market ambitions, though U.S. adoption lags. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
Outlook remains cautious due to technical weakness and competitive pressures in the EV sector. Opportunities exist from rising global EV demand, but risks include regulatory hurdles and market volatility. Investors should await clearer financial metrics for a full evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →
